GZMB+ B cells:	Granzyme B positive B cells with regulatory properties.
Induced GZMB+ B cells:	GZMB+ B cells generated according to the in vitro protocol described in Chesneau et al. [19].
Natural GZMB+ B cells:	B cells from donor’s blood or biopsies expressing GZMB without any restimulation in vitro.
GZMB− B cells:	B cells used to determine the characteristics of GZMB+ B cells. For the dataset generated after in vitro induction, GZMB− B cells correspond to the conditions that did not receive any stimulation (i.e., total resting B cells after 3 days), as GZMB expression is transient.
TOL:	Patients with no immunosuppression for at least one year and with stable creatinine < 150 mmol/L and proteinuria < 1 g/24.
STA:	Patients with stable graft function (creatinine < 150 mmol/L and proteinuria < 0.2 g/g creatinine) for at least 3 years under standard immunosuppression (calcineurin inhibitors [CNIs], antimetabolite ± corticosteroids).
ABMR:	Patients with histology-proven antibody-mediated rejection.
DEG:	Differentially expressed gene.